
    inefficiency
  
['thyroid cancer']
['gemcitabine -oxaliplatine combination']

        "Main Inclusion criteria

          1. Histologically confirmed differentiated or poorly differentiated thyroid cancer that
             is metastatic or unresectable

          2. Patients refractory to radio iodine

          3. Radiologic evidence of clinically relevant disease progression (as per RECIST 1.1)

          4. Measurable disease (by RECIST Version 1.1 criteria)

          5. ECOG performance status of ≤ 1

          6. Adequate hematologic, renal and liver function

          7. Negative serum pregnancy test in premenopausal women.

          8. Signed informed consent

        Main Non-Inclusion criteria

          1. Other histological subtypes of thyroid tumors: anaplastic, medullary, lymphoma or
             sarcoma

          2. Active CNS metastases

          3. Prior chemotherapy. Patients treated previously with molecular targeted therapies
             could be included.

          4. Severe, acute or chronic medical or psychiatric condition or laboratory abnormality
             which in the judgment of the investigator would make the patient inappropriate for
             entry into this study"
      